



*Reap*

ATTORNEY DOCKET NO. 14014.0312  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of	)	
	)	
Strober et al.	)	Group Art Unit: 1642
	)	
Serial No. 09/196,867	)	Examiner: Unassigned
	)	
Filed: November 20, 1998	)	
	)	
For: METHODS OF USING CR3 AND CR4	)	
LIGANDS FOR INHIBITING	)	
INTERLEUKIN-12 TO TREAT	)	
AUTOIMMUNE DISEASE	)	

**MAR 05 1999**

**GROUP**

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, DC 20231

NEEDLE & ROSENBERG, P.C.  
The Candler Building  
Suite 1200  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811

February 15, 1999

Sir:


In response to the Filing Receipt issued in the above-identified application, we hereby formally request that a corrected Filing Receipt be issued, because of the incorrect listing of the applicants. The Filing Receipt (a copy of which is enclosed) lists the applicants as follows: Brian Kelsall, Warren Strobber, Fuss Ivan and Thomas Marth. Applicants note that Strobber is misspelled, it should read "Strober", and Fuss Ivan should read "Ivan Fuss". Thus, the correct list of applicants should read: Brian Kelsall, Warren Strober, Ivan Fuss and Thomas Marth. A copy of page 1 of the Application Transmittal Form, which was filed with the U.S. Patent and Trademark Office on November 20, 1998, is enclosed. Also enclosed is a copy of the first page of the application as filed. Both of these documents correctly list the inventors. Therefore, applicants respectfully request that a corrected filing receipt be issued.

**ATTORNEY DOCKET NO. 14014.0312**  
**SERIAL NO. 09/196,867**

No fee is believed to be due; however, the Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Mary L. Miller  
Reg. No. 39,303

Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811  
(404) 688-0770

**CERTIFICATE OF MAILING**


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on February 15, 1999.

  
Mary L. Miller

February 15, 1999  
Date

W009929

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/196,867	11/20/98	1642	\$0.00	14014.0312	0	29	8

MARY L. MILLER  
NEEDLE & ROSENBERG  
SUITE 1200, THE CANDLER BULDG  
127 PEACHTREE STREET, N.E.  
ATLANTA GA 30303-1811

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

BRIAN KELSALL, WASHINGTON, DC; WARREN STROBBER,  
BETHESDA, MD; FUSS IVAN, BETHESDA, MD; THOMAS MARTH,  
KENSINGTON, MD.


CONTINUING DATA AS CLAIMED BY APPLICANT-  
PROVISIONAL APPLICATION NO. 60/066,238 11/20/97

FOREIGN FILING LICENSE GRANTED 12/07/98

TITLE

METHODS OF USING CR3 AND CR4 LIGANDS FOR INHIBITING INTERLEUKIN-12 TO  
TREAT AUTOIMMUNE DISEASE

PRELIMINARY CLASS: 424



DATA ENTRY BY: OKON, THERESA

TEAM: 02 DATE: 12/11/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
 Assistant Commissioner for Patents  
 Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.  
 Suite 1200, The Candler Building  
 127 Peachtree Street, N.E.  
 Atlanta, Georgia 30303-1811

November 20, 1998



Dear Sir:

Transmitted herewith for filing are the specification and claims of the patent application of:

Inventor(s): BRIAN KELSALL, WARREN STROBER, IVAN FUSS and THOMAS MARTH

Title of Invention: METHODS OF USING CR3 AND CR4 LIGANDS FOR INHIBITING INTERLEUKIN-12 TO TREAT AUTOIMMUNE DISEASE

Also enclosed are:

	SHEETS OF	<input type="checkbox"/> FORMAL DRAWINGS	<input type="checkbox"/> INFORMAL DRAWINGS
	OATH OR DECLARATION OF APPLICANT(S)		
	A POWER OF ATTORNEY		
	A PRELIMINARY AMENDMENT		
	A VERIFIED STATEMENT TO ESTABLISH SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9 AND §1.27		
	A CHECK IN THE AMOUNT OF TO COVER THE FILING FEE.		
	THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY ADDITIONAL FEES WHICH MAY BE REQUIRED IN CONNECTION WITH THE FOLLOWING OR CREDIT ANY OVERPAYMENT TO ACCOUNT NO.		
	A CERTIFIED COPY OF PREVIOUSLY FILED FOREIGN APPLICATION NO. FILED IN ON .		
X	I hereby certify that this correspondence is being placed in the United States Mail as Express Mail No. EL211203234us on November 20, 1998.   DATE		
	A computer readable form of the sequence listing in compliance with 37 C.F.R. § 1.821(e). The content of the computer readable form of the sequence listing and the sequence listing in the specification of the application as filed are the same.		
	OTHER (IDENTIFY)		

The filing fee is calculated as follows:

5

10

15

TO ALL WHOM IT MAY CONCERN:

Be it known that we, BRIAN KELSALL, WARREN STROBER, and IVAN  
FUSS, citizens of the United States of America, and THOMAS MARTH, a citizen of  
20 Germany, residing at 5030 Eskridge Terr., N.W., Washington, D.C. 20016, 8301  
Whittier Blvd., Bethesda, MD 20817, 4801 Fairmont Avenue, Apt. 407, Bethesda, MD  
20814, and 4515 Dresden Street, Kensington, MD 20895, U.S.A., respectively, have  
invented new and useful improvements in

25

**METHODS OF USING CR3 AND CR4 LIGANDS FOR  
INHIBITING INTERLEUKIN-12 TO TREAT AUTOIMMUNE DISEASE**

for which the following is a specification.